Hycamtin
Recurrent Childhood Visual Pathway Glioma
City of Hope Medical CenterPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Recurrent Childhood Visual Pathway Glioma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan National Cancer Institute (NCI) | Phase 2 | BB |
Busulphan City of Hope Medical Center | Phase 1 | CC |
Vorinostat National Cancer Institute (NCI) | Phase 1 | CC |
FILGRASTIM City of Hope Medical Center | Phase 1 | CC |
gw786034 National Cancer Institute (NCI) | Phase 1 | CC |
View all 12 →
Same molecule, other indications
Hycamtin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →